Epidemiology of Breast Cancer Mortality in Kazakhstan, trends and Geographic Distribution.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 10 2023
Historique:
received: 26 09 2022
medline: 30 10 2023
pubmed: 29 10 2023
entrez: 29 10 2023
Statut: epublish

Résumé

According to the International Agency for Research on Cancer, ongoing demographic changes will lead to an increase in the number of deaths from breast cancer (BC) per year in the vast majority of regions. In 2040 it is expected that 1.04 million people worldwide will die from this malignancy, including 2,380 women in Kazakhstan. The retrospective study (2009-2018) was done using descriptive and analytical methods of oncoepidemiology. The extensive, crude and age-specific incidence rates are determined according to the generally accepted methodology used in sanitary statistics. The data were used to calculate the average percentage change (APС) using the Joinpoint regression analysis to determine the trend over the study period. During 10 years 12,958 women died from BC. An average age of the death was 61.6 years (95%CI=60.6-62.6) and tended to increase (APC=+0.6%, R2=0.6117). Age-specific rates had a bimodal increase with peak rates at 70-74 years - 76.7±5.5 (APC=+3.4%, R2=0.2656) and 80-84 years - 78.0±9.1 (APC=+3.7%, R2=0.0875). The age-standardized rate was 13.9 per 100,000 of female population, and the trend has decreased. When compiling thematic maps, mortality rates were determined on the basis of standardized indicators: low - up to 12.5, average - from 12.5 to 15.2, high - above 15.2 per 100,000. The results of the spatial analysis showed the regions with a higher levels of BC mortality rate per 100,000: Pavlodar (16.9), Almaty (19.2) and Astana cities (19.3). Age-standardized mortality rates had a strong downward trend (APC=-4.0%, R2=0.9218). The decrease mostly is due to a large coverage of the population by mammography screening and to an improvement in the effectiveness of breast cancer treatment.

Sections du résumé

BACKGROUND
According to the International Agency for Research on Cancer, ongoing demographic changes will lead to an increase in the number of deaths from breast cancer (BC) per year in the vast majority of regions. In 2040 it is expected that 1.04 million people worldwide will die from this malignancy, including 2,380 women in Kazakhstan.
METHODS
The retrospective study (2009-2018) was done using descriptive and analytical methods of oncoepidemiology. The extensive, crude and age-specific incidence rates are determined according to the generally accepted methodology used in sanitary statistics. The data were used to calculate the average percentage change (APС) using the Joinpoint regression analysis to determine the trend over the study period.
RESULTS
During 10 years 12,958 women died from BC. An average age of the death was 61.6 years (95%CI=60.6-62.6) and tended to increase (APC=+0.6%, R2=0.6117). Age-specific rates had a bimodal increase with peak rates at 70-74 years - 76.7±5.5 (APC=+3.4%, R2=0.2656) and 80-84 years - 78.0±9.1 (APC=+3.7%, R2=0.0875). The age-standardized rate was 13.9 per 100,000 of female population, and the trend has decreased. When compiling thematic maps, mortality rates were determined on the basis of standardized indicators: low - up to 12.5, average - from 12.5 to 15.2, high - above 15.2 per 100,000. The results of the spatial analysis showed the regions with a higher levels of BC mortality rate per 100,000: Pavlodar (16.9), Almaty (19.2) and Astana cities (19.3).
CONCLUSIONS
Age-standardized mortality rates had a strong downward trend (APC=-4.0%, R2=0.9218). The decrease mostly is due to a large coverage of the population by mammography screening and to an improvement in the effectiveness of breast cancer treatment.

Identifiants

pubmed: 37898839
doi: 10.31557/APJCP.2023.24.10.3361
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3361-3371

Auteurs

Nurbek Igissinov (N)

Research Institute of Life and Health Sciences, Faculty of Medicine, Kokshetau University named after Sh. Ualikhanov, Kokshetau, Kazakhstan.
Central Asian Institute for Medical Research, Astana, Kazakhstan.
Asian Pacific Organization for Cancer Prevention, Bishkek, Kyrgyzstan.

Assem Toguzbayeva (A)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.

Zaituna Khamidullina (Z)

Astana Medical University, Astana, Kazakhstan.

Zhansaya Telmanova (Z)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Asian Pacific Organization for Cancer Prevention, Bishkek, Kyrgyzstan.

Zarina Bilyalova (Z)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Asian Pacific Organization for Cancer Prevention, Bishkek, Kyrgyzstan.

Indira Kudaibergenova (I)

Asian Pacific Organization for Cancer Prevention, Bishkek, Kyrgyzstan.
Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan.

Svetlana Muratbekova (S)

Research Institute of Life and Health Sciences, Faculty of Medicine, Kokshetau University named after Sh. Ualikhanov, Kokshetau, Kazakhstan.

Gulnur Igissinova (G)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.

Kulsara Rustemova (K)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Astana Medical University, Astana, Kazakhstan.

Dariyana Kulmirzayeva (D)

Central Asian Institute for Medical Research, Astana, Kazakhstan.

Nariman Syzdykov (N)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Health Department of the Akmola region, Kokshetau, Kazakhstan.

Rustem Taszhanov (R)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Kokshetau Higher Medical College, Kokshetau, Kazakhstan.

Dulat Turebayev (D)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Astana Medical University, Astana, Kazakhstan.

Galiya Orazova (G)

Astana Medical University, Astana, Kazakhstan.

Dinara Kassenova (D)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Astana Medical University, Astana, Kazakhstan.

Violetta Detochkina (V)

Astana Medical University, Astana, Kazakhstan.

Daulet Baibosynov (D)

Central Asian Institute for Medical Research, Astana, Kazakhstan.
Astana Medical University, Astana, Kazakhstan.

Yerlan Kuandykov (Y)

Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, Kazakhstan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH